FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2603199396> ?p ?o ?g. }

• W2603199396 endingPage "511" @default.
• W2603199396 startingPage "503" @default.
• W2603199396 abstract "Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) downregulates low-density lipoprotein (LDL) receptors, thereby leading to a rise in circulating LDL cholesterol (LDL-C). RG7652 is a fully human monoclonal antibody against PCSK9. This placebo-controlled, phase 1 ascending-dose study in healthy subjects evaluated the safety of RG7652 and its efficacy as a potential LDL-C–lowering drug. Hypothesis Anti-PCSK9 antibody therapy safely and effectively reduces LDL-C. Methods Subjects (N = 80) were randomized into 10 cohorts. Six sequential single-dose cohorts received 10, 40, 150, 300, 600, or 800 mg of RG7652 via subcutaneous injection. Four multiple-dose cohorts received 40 or 150 mg of RG7652 once weekly for 4 weeks, either with or without statin therapy (atorvastatin). Results Adverse events (AEs) were generally mild; the most common AEs were temporary injection-site reactions. No serious AEs, severe AEs, AEs leading to study-drug discontinuation, or dose-limiting toxicities were reported. RG7652 monotherapy reduced mean LDL-C levels by up to 64% and as much as 100 mg/dL at week 2; the effect magnitude and duration increased with dose (≥57 days following a single RG7652 dose ≥300 mg). Exploratory analyses showed reduced oxidized LDL, lipoprotein(a), and lipoprotein-associated phospholipase A2 with RG7652. Antidrug antibody against RG7652 tested positive in 2 of 60 (3.3%) RG7652-treated and in 4 of 20 (20.0%) placebo-treated subjects. Simultaneous atorvastatin administration did not appear to impact the pharmacokinetic profile or lipid-lowering effects of RG7652. Conclusions Overall, RG7652 elicited substantial and sustained dose-related LDL-C reductions with an acceptable safety profile and minimal immunogenicity." @default.
• W2603199396 created "2017-04-07" @default.
• W2603199396 creator A5004768427 @default.
• W2603199396 creator A5017876287 @default.
• W2603199396 creator A5028092177 @default.
• W2603199396 creator A5028349586 @default.
• W2603199396 creator A5046377363 @default.
• W2603199396 creator A5047810971 @default.
• W2603199396 creator A5072975032 @default.
• W2603199396 creator A5078590150 @default.
• W2603199396 creator A5082749535 @default.
• W2603199396 creator A5082898036 @default.
• W2603199396 creator A5083088355 @default.
• W2603199396 creator A5090774902 @default.
• W2603199396 date "2017-03-22" @default.
• W2603199396 modified "2023-09-24" @default.
• W2603199396 title "A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9" @default.
• W2603199396 cites W162053157 @default.
• W2603199396 cites W1989730880 @default.
• W2603199396 cites W2001313012 @default.
• W2603199396 cites W2001592913 @default.
• W2603199396 cites W2040612932 @default.
• W2603199396 cites W2053513183 @default.
• W2603199396 cites W2067539811 @default.
• W2603199396 cites W2080443045 @default.
• W2603199396 cites W2086717183 @default.
• W2603199396 cites W2093535758 @default.
• W2603199396 cites W2103647780 @default.
• W2603199396 cites W2104355263 @default.
• W2603199396 cites W2108956796 @default.
• W2603199396 cites W2114408062 @default.
• W2603199396 cites W2117011155 @default.
• W2603199396 cites W2143064104 @default.
• W2603199396 cites W2172024977 @default.
• W2603199396 cites W2569152759 @default.
• W2603199396 cites W72392028 @default.
• W2603199396 doi "https://doi.org/10.1002/clc.22687" @default.
• W2603199396 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6490403" @default.
• W2603199396 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28326559" @default.
• W2603199396 hasPublicationYear "2017" @default.
• W2603199396 type Work @default.
• W2603199396 sameAs 2603199396 @default.
• W2603199396 citedByCount "16" @default.
• W2603199396 countsByYear W26031993962015 @default.
• W2603199396 countsByYear W26031993962017 @default.
• W2603199396 countsByYear W26031993962018 @default.
• W2603199396 countsByYear W26031993962019 @default.
• W2603199396 countsByYear W26031993962020 @default.
• W2603199396 countsByYear W26031993962021 @default.
• W2603199396 countsByYear W26031993962022 @default.
• W2603199396 countsByYear W26031993962023 @default.
• W2603199396 crossrefType "journal-article" @default.
• W2603199396 hasAuthorship W2603199396A5004768427 @default.
• W2603199396 hasAuthorship W2603199396A5017876287 @default.
• W2603199396 hasAuthorship W2603199396A5028092177 @default.
• W2603199396 hasAuthorship W2603199396A5028349586 @default.
• W2603199396 hasAuthorship W2603199396A5046377363 @default.
• W2603199396 hasAuthorship W2603199396A5047810971 @default.
• W2603199396 hasAuthorship W2603199396A5072975032 @default.
• W2603199396 hasAuthorship W2603199396A5078590150 @default.
• W2603199396 hasAuthorship W2603199396A5082749535 @default.
• W2603199396 hasAuthorship W2603199396A5082898036 @default.
• W2603199396 hasAuthorship W2603199396A5083088355 @default.
• W2603199396 hasAuthorship W2603199396A5090774902 @default.
• W2603199396 hasBestOaLocation W26031993961 @default.
• W2603199396 hasConcept C112705442 @default.
• W2603199396 hasConcept C126322002 @default.
• W2603199396 hasConcept C134018914 @default.
• W2603199396 hasConcept C142724271 @default.
• W2603199396 hasConcept C197934379 @default.
• W2603199396 hasConcept C204787440 @default.
• W2603199396 hasConcept C27081682 @default.
• W2603199396 hasConcept C2776839432 @default.
• W2603199396 hasConcept C2777482532 @default.
• W2603199396 hasConcept C2778114629 @default.
• W2603199396 hasConcept C2778163477 @default.
• W2603199396 hasConcept C2778824825 @default.
• W2603199396 hasConcept C2778849439 @default.
• W2603199396 hasConcept C2780072125 @default.
• W2603199396 hasConcept C2780745583 @default.
• W2603199396 hasConcept C2780948078 @default.
• W2603199396 hasConcept C43554185 @default.
• W2603199396 hasConcept C71924100 @default.
• W2603199396 hasConcept C98274493 @default.
• W2603199396 hasConceptScore W2603199396C112705442 @default.
• W2603199396 hasConceptScore W2603199396C126322002 @default.
• W2603199396 hasConceptScore W2603199396C134018914 @default.
• W2603199396 hasConceptScore W2603199396C142724271 @default.
• W2603199396 hasConceptScore W2603199396C197934379 @default.
• W2603199396 hasConceptScore W2603199396C204787440 @default.
• W2603199396 hasConceptScore W2603199396C27081682 @default.
• W2603199396 hasConceptScore W2603199396C2776839432 @default.
• W2603199396 hasConceptScore W2603199396C2777482532 @default.
• W2603199396 hasConceptScore W2603199396C2778114629 @default.
• W2603199396 hasConceptScore W2603199396C2778163477 @default.
• W2603199396 hasConceptScore W2603199396C2778824825 @default.
• W2603199396 hasConceptScore W2603199396C2778849439 @default.
• W2603199396 hasConceptScore W2603199396C2780072125 @default.

• next